Common Side Effects Patients Report
Ozempic (semaglutide) causes gastrointestinal issues in many users, including nausea (up to 44% in trials), vomiting (24%), diarrhea (30%), abdominal pain (20%), and constipation (24%). These often start early and decrease over time but lead to discontinuation in about 4-7% of patients.[1][2]
Serious Risks Highlighted in Warnings
The FDA black box warns of thyroid C-cell tumors risk, based on rodent studies; human risk is unclear but prompts monitoring for symptoms like neck lumps.[1] Other concerns include:
- Pancreatitis (0.3 cases per 100 patient-years vs. 0.2 for placebo).[2]
- Gallbladder issues like cholelithiasis (1.5% vs. 0.4%).[2]
- Acute kidney injury from dehydration due to GI effects.[1]
- Hypoglycemia risk when combined with insulin or sulfonylureas.[1]
Vision changes (diabetic retinopathy complications) occurred in 3% of patients with prior retinopathy.[2]
Long-Term Concerns and "Ozempic Face"
Prolonged use raises questions about muscle loss and "Ozempic face"—sagging skin from rapid weight loss, affecting facial fat without muscle preservation strategies like exercise or protein intake. Bone density loss is also under study, with some data showing slower bone formation.[3][4] No direct cancer link beyond thyroid tumors in animals, but ongoing monitoring for gastrointestinal cancers.[5]
Recent FDA Updates and Investigations
In 2023, FDA added warnings for ileus (intestinal blockage) after 45 reports, including one death. Suits allege inadequate GI risk disclosure. Compounded semaglutide versions face FDA alerts for dosing errors and contamination, with over 100 hospitalizations.[6][7] No recalls for branded Ozempic, but supply shortages amplified scrutiny.
Who Should Avoid Ozempic
Contraindicated in those with personal/family medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Use caution in gastroparesis, severe GI disease, or history of pancreatitis. Pregnancy category C; discontinue 2 months prior.[1]
How Risks Compare to Benefits
Trials show 1-2% serious adverse events rate, lower than many diabetes drugs, with cardiovascular benefits (14% lower major events).[2][8] Weight loss users report higher GI tolerance at lower doses. Always pair with lifestyle changes to mitigate muscle/bone risks.
[1]: FDA Ozempic Label
[2]: NEJM SUSTAIN-6 Trial
[3]: JAMA Muscle Loss Study
[4]: Endocrine Society Ozempic Face
[5]: FDA Adverse Events
[6]: FDA Ileus Warning
[7]: [FDA Compounded Alert](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-potential-risks-associated- compounded)
[8]: SELECT Trial CV Outcomes